David Venables
Amministratore Delegato presso Synpromics Ltd.
Posizioni attive di David Venables
Società | Posizione | Inizio | Fine |
---|---|---|---|
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Amministratore Delegato | - | - |
Direttore/Membro del Consiglio | 15/12/2014 | 07/08/2019 | |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | 01/08/2021 | - |
Storia della carriera di David Venables
Precedenti posizioni note di David Venables
Società | Posizione | Inizio | Fine |
---|---|---|---|
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 02/08/2012 | 27/02/2015 |
Corporate Officer/Principal | 16/04/2012 | 02/08/2012 | |
ANATARA LIFESCIENCES LTD | Direttore/Membro del Consiglio | 17/02/2014 | 24/02/2015 |
Amministratore Delegato | 17/02/2014 | 24/02/2015 | |
Q-One Biotech Ltd. | Corporate Officer/Principal | - | - |
Medeva Plc | Corporate Officer/Principal | - | - |
IOMAI CORPORATION | Direttore operativo | - | - |
Formazione di David Venables
University of Surrey | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 7 |
Stati Uniti | 2 |
Australia | 2 |
Posizioni
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 3 |
Settori
Health Technology | 6 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ANATARA LIFESCIENCES LTD | Health Technology |
Aziende private | 6 |
---|---|
Medeva Plc | Health Technology |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Commercial Services |
Q-One Biotech Ltd. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Process Industries |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Health Technology |
- Borsa valori
- Insiders
- David Venables
- Esperienza